Archive: November 24, 2019

24

Nov2019

A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

0  
November 24, 2019